DK2121944T3 - In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser - Google Patents

In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser

Info

Publication number
DK2121944T3
DK2121944T3 DK08707977.8T DK08707977T DK2121944T3 DK 2121944 T3 DK2121944 T3 DK 2121944T3 DK 08707977 T DK08707977 T DK 08707977T DK 2121944 T3 DK2121944 T3 DK 2121944T3
Authority
DK
Denmark
Prior art keywords
qpct
treatment
alzheimer
disease
related disorders
Prior art date
Application number
DK08707977.8T
Other languages
Danish (da)
English (en)
Inventor
Stephan Schilling
Holger Cynis
Torsten Hoffmann
Hans-Ulrich Demuth
Michael Wermann
Katrin Schulz
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Application granted granted Critical
Publication of DK2121944T3 publication Critical patent/DK2121944T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Rheumatology (AREA)
  • Animal Husbandry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
DK08707977.8T 2007-01-19 2008-01-18 In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser DK2121944T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88564907P 2007-01-19 2007-01-19
PCT/EP2008/050532 WO2008087197A1 (en) 2007-01-19 2008-01-18 In vivo screening models for treatment of alzheimer's disease and other qpct-related disorders

Publications (1)

Publication Number Publication Date
DK2121944T3 true DK2121944T3 (da) 2011-10-31

Family

ID=39271322

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08707977.8T DK2121944T3 (da) 2007-01-19 2008-01-18 In vivo screeningsmodeller til behandling af Alzheimers sygdom og andre QPCT-relaterede lidelser

Country Status (13)

Country Link
US (1) US20080200567A1 (enExample)
EP (2) EP2395095A1 (enExample)
JP (1) JP2010516235A (enExample)
AT (1) ATE521711T1 (enExample)
AU (1) AU2008206936B2 (enExample)
CA (1) CA2675192A1 (enExample)
DK (1) DK2121944T3 (enExample)
ES (1) ES2372229T3 (enExample)
HR (1) HRP20110651T1 (enExample)
NZ (1) NZ578513A (enExample)
SI (1) SI2121944T1 (enExample)
WO (1) WO2008087197A1 (enExample)
ZA (1) ZA200904353B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9277737B2 (en) 2006-09-21 2016-03-08 Probiodrug Ag Mouse models carrying a knock-out mutation of the QPCTL-gene
WO2008110523A1 (en) * 2007-03-09 2008-09-18 Probiodrug Ag Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
JP5675341B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体
ES2468551T3 (es) * 2007-04-18 2014-06-16 Probiodrug Ag Derivados de nitrovinil-diamina como inhibidores de la glutaminil ciclasa
WO2008128985A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
JP5675343B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としての尿素誘導体
EP2142515B1 (en) * 2007-04-18 2014-03-26 Probiodrug AG Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
EP2160380B1 (en) * 2007-04-18 2014-04-02 Probiodrug AG Cyano-guanidine derivatives as glutaminyl cyclase inhibitors
JP5676249B2 (ja) * 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
AU2008297070A1 (en) * 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
WO2009090190A1 (en) * 2008-01-14 2009-07-23 Probiodrug Ag Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene
EA025107B1 (ru) * 2008-07-31 2016-11-30 Пробиодруг Аг Способ диагностирования болезни альцгеймера, нейродегенерации при синдроме дауна или легкого когнитивного нарушения у субъекта (варианты) и набор для осуществления способа
US11219696B2 (en) * 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
ES2540467T3 (es) 2010-08-19 2015-07-09 Probiodrug Ag Estructura cristalina de glutaminil ciclasa
JP2013541938A (ja) 2010-09-02 2013-11-21 プロビオドルグ エージー アイソｑｃ関連障害の治療のためのインビボスクリーニングモデル
US8741614B2 (en) 2010-11-02 2014-06-03 Probiodrug Ag Crystal structure of isoglutaminyl cyclase
WO2013024043A2 (en) 2011-08-12 2013-02-21 Probiodrug Ag In vivo screening models for treatment of qc-related disorders
CA2880653C (en) 2012-08-01 2022-05-17 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
US20180318260A1 (en) * 2015-11-04 2018-11-08 The Scripps Research Institute Compositions and methods for treating cystic fibrosis
MC200185B1 (fr) 2016-09-16 2017-10-04 Coronal Audio Dispositif et procédé de captation et traitement d'un champ acoustique tridimensionnel
MC200186B1 (fr) 2016-09-30 2017-10-18 Coronal Encoding Procédé de conversion, d'encodage stéréophonique, de décodage et de transcodage d'un signal audio tridimensionnel

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
JPH07132033A (ja) * 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
US6948038B2 (en) * 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
KR20060009902A (ko) * 2003-05-05 2006-02-01 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
PL1620082T3 (pl) 2003-05-05 2010-10-29 Probiodrug Ag Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa
EP1620091B1 (en) * 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2004290499C1 (en) * 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005075436A2 (en) * 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
GB0704100D0 (en) 2006-03-17 2007-04-11 Vodafone Plc Improvements in an ehspa architecture
WO2008034891A2 (en) * 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase

Also Published As

Publication number Publication date
WO2008087197A1 (en) 2008-07-24
NZ578513A (en) 2012-01-12
EP2121944B1 (en) 2011-08-24
SI2121944T1 (sl) 2011-12-30
JP2010516235A (ja) 2010-05-20
EP2395095A1 (en) 2011-12-14
ES2372229T3 (es) 2012-01-17
US20080200567A1 (en) 2008-08-21
AU2008206936B2 (en) 2013-03-14
ATE521711T1 (de) 2011-09-15
HRP20110651T1 (hr) 2011-10-31
AU2008206936A1 (en) 2008-07-24
EP2121944A1 (en) 2009-11-25
CA2675192A1 (en) 2008-07-24
ZA200904353B (en) 2010-09-29

Similar Documents

Publication Publication Date Title
ZA200904353B (en) In vivo screening models for treatment of alzheimer's disease and other Qpct-related disorders
WO2009034158A3 (en) Transgenic mice
CY1121252T1 (el) Anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2008121199A3 (en) Transgenic animal models of disease
CY2016023I1 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9(pcsk9)
NO20076563L (no) Anti- MCP-1 antistoffer, sammensetninger og anvendelser
CR11434A (es) Anticuerpos anti-amiloide humanos; composiciones, metodosy usos
DK3156414T3 (da) Syntetisk 5'utrs ekspressionsvektorer og fremgangsmåder til øgning af transgen ekspression
ATE462787T1 (de) Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington
UA111934C2 (uk) ТРАНСГЕННА РОСЛИНА, ЩО МІСТИТЬ ДНК, ЯКА КОДУЄ ІНСЕКТИЦИДНИЙ БІЛОК Vip3Ab, І ДНК, ЯКА КОДУЄ ІНСЕКТИЦИДНИЙ БІЛОК Cry1Fa, СТІЙКА ДО ЛУСКОКРИЛИХ ШКІДНИКІВ
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
WO2007111938A3 (en) Inflammation-inhibitory serum factors and uses thereof
EA200900210A1 (ru) Способ и набор для прогнозирования успеха имплантации при искусственном оплодотворении
ATE541059T1 (de) Verfahren für den nachweis von entzündlicher darmerkrankung
EP3678484A4 (en) MODIFIED ANIMAL ORGANS FOR USE IN SURGICAL SIMULATORS
CY2016036I2 (el) Μεθοδοι θεραπειας πολλαπλου μυελωματος χρησιμοποιωντας θεραπειες συνδυασμου που βασιζονται σε αντισωματα anti-cs1
Castillo-Mariqueo et al. Clasping, ledge-score coordination and early gait impairments as primary behavioural markers of functional impairment in Alzheimer's disease
UA110774C2 (uk) Нетрансгенна стійка до посухи рослина
Rezzani et al. Morphological and biochemical studies on aging and autophagy
WO2008153543A3 (en) Fluorescent mouse model
ATE511348T1 (de) Transgenes modell für morbus alzheimer
EP2385115A4 (en) EXPRESSION VECTOR FOR THE MANUFACTURE OF A FREEDOM DERIVED PROTEIN IN LARGE QUANTITY USING ANIMAL CELLS AND USE THEREOF
ATE443991T1 (de) Verwendung von phenylsemicarbazonen für die saatgutbeizung
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
EP2415868A4 (en) METHOD AND KIT FOR EVALUATING THE PRESENT POSITION FOR THE DEVELOPMENT OF ADIPOSITAS, ACTIVE AGAINST ADIPOSITAS AND SCREENING METHOD, NON-MENTAL ANIMAL, ADIPOUS TISSUE, ADIPOCYTE, PROCESS FOR THE MANUFACTURE OF TRANSGENIC MICE, ANTIGEN AND ANTIBODIES